These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7783139)

  • 21. Analysis of cocaine receptor site ligand binding by three-dimensional Voronoi site modeling approach.
    Srivastava S; Crippen GM
    J Med Chem; 1993 Nov; 36(23):3572-9. PubMed ID: 8246225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping the binding site of the nucleoside transporter protein: a 3D-OSAR study.
    Viswanadhan VN; Ghose AK; Weinstein JN
    Biochim Biophys Acta; 1990 Jul; 1039(3):356-66. PubMed ID: 2378893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
    Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
    Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computer design of bioactive compounds based on 3-D properties of ligands.
    Martin YC
    NIDA Res Monogr; 1993; 134():84-102. PubMed ID: 8289889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-dimensional QSAR in drug research. Predicting binding affinities, toxicity and pharmacokinetic parameters.
    Vedani A; Dobler M
    Prog Drug Res; 2000; 55():105-35. PubMed ID: 11127962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel C3V-symmetric tripodal scaffold, triethyl cis,cis,cis-2,5,8- tribenzyltrindane-2,5,8-tricarboxylate, for the construction of artificial receptors.
    Choi HJ; Park YS; Yun SH; Kim HS; Cho CS; Ko K; Ahn KH
    Org Lett; 2002 Mar; 4(5):795-8. PubMed ID: 11869130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacophore and pseudoreceptor modelling of class Ib antiarrhythmic and local anaesthetic lidocaine analogues.
    Schleifer KJ; Tot E; Höltje HD
    Pharmazie; 1998 Sep; 53(9):596-602. PubMed ID: 9770207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Energetics of the cleft closing transition and the role of electrostatic interactions in conformational rearrangements of the glutamate receptor ligand binding domain.
    Mamonova T; Yonkunas MJ; Kurnikova MG
    Biochemistry; 2008 Oct; 47(42):11077-85. PubMed ID: 18823129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular electrostatic potential as a factor of drug-receptor recognition.
    Dukhovich FS; Darkhovskii MB
    J Mol Recognit; 2003; 16(4):191-202. PubMed ID: 12898669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure prediction of protein-solid surface interactions reveals a molecular recognition motif of statherin for hydroxyapatite.
    Makrodimitris K; Masica DL; Kim ET; Gray JJ
    J Am Chem Soc; 2007 Nov; 129(44):13713-22. PubMed ID: 17929924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
    Frembgen-Kesner T; Elcock AH
    J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactive computer surface graphics approach to study of the active site of bovine trypsin.
    Feldmann RJ; Bing DH; Furie BC; Furie B
    Proc Natl Acad Sci U S A; 1978 Nov; 75(11):5409-12. PubMed ID: 281690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unveiling the full potential of flexible receptor docking using multiple crystallographic structures.
    Barril X; Morley SD
    J Med Chem; 2005 Jun; 48(13):4432-43. PubMed ID: 15974595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular modeling of sigma 1 receptor ligands: a model of binding conformational and electrostatic considerations.
    Gund TM; Floyd J; Jung D
    J Mol Graph Model; 2004 Jan; 22(3):221-30. PubMed ID: 14629980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A model for the antagonist binding site on the adenosine A1 receptor, based on steric, electrostatic, and hydrophobic properties.
    van Galen PJ; van Vlijmen HW; IJzerman AP; Soudijn W
    J Med Chem; 1990 Jun; 33(6):1708-13. PubMed ID: 2342066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ligand-ligand and ligand-receptor approaches to modeling the cannabinoid CB1 and CB2 receptors: achievements and challenges.
    Reggio PH
    Curr Med Chem; 1999 Aug; 6(8):665-83. PubMed ID: 10469885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a functionally important negatively charged residue within the second catalytic site of the SUR1 nucleotide-binding domains.
    Campbell JD; Proks P; Lippiat JD; Sansom MS; Ashcroft FM
    Diabetes; 2004 Dec; 53 Suppl 3():S123-7. PubMed ID: 15561899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From genomics to drug targets.
    Dahl SG; Sylte I
    J Psychopharmacol; 2006 Jul; 20(4 Suppl):95-9. PubMed ID: 16785277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
    Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
    J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structures of enzyme-substrate complexes of lysozyme.
    Pincus MR; Zimmerman SS; Scheraga HA
    Proc Natl Acad Sci U S A; 1977 Jul; 74(7):2629-33. PubMed ID: 268614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.